FRONTIER : FReeStyle Libre system use in Ontario among people with diabetes in the IC / ES database—Evidence from real‐world practice: Patients on basal insulin, glucagon‐like peptide 1 receptor agonist or oral therapies
Authors' conclusion
Among people with T2DM using basal insulin and/or non-insulin therapies, HbA1c levels were statistically significantly improved and HCRU was reduced after initiation of FSL.
Study context
- Population
- People with T2DM with a first FSL claim between 16 September 2019 and 31 August 2020, active on FSL for 24 months' follow-up; IC/ES administrative data, Ontario, Canada
- Participants
- 20,253 people
- Exposure
- After vs before FSL acquisition
- Outcome
- Mean HbA1c after vs before FSL acquisition
Methodological detailsbefore-and-after comparison, routinely collected administrative health data
- Before-and-after comparison
- Routinely collected administrative health data
Main finding
As reported in the abstract
Mean HbA1c significantly reduced after FSL acquisition, aged ≤65 or >65 years, in all four treatment groups (range of reduction)
0.3-0.8%
Observational data: associations, not effects.
Further findings
Healthcare resource utilization (HCRU) (ED visits, hospitalization), last 12 months of 24-month follow-up vs 12 months before index
- ED visits and hospitalization significantly reduced in the oral therapy only group and in some basal insulin subgroups (without GLP-1 RA, all except hospitalization aged ≤65 years; with GLP-1 RA, only ED visits aged ≤65 years)
Original publication
FRONTIER : FReeStyle Libre system use in Ontario among people with diabetes in the IC / ES database—Evidence from real‐world practice: Patients on basal insulin, glucagon‐like peptide 1 receptor agonist or oral therapies. Diabetes Obes Metab. Published 21 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →